证券代码：002317 编号：2017-009 第 1 页/共 4 页 广东众生药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------------------|------------------------------------------------------| | | √ □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □一对一沟通 | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 1 、 建信基金管理有限责任公司 | 许杰 | | 时间 | 2017 年 9 月 14 日 9:30 ～ | 10:30 | | 地点 | 广东众生药业股份有限公司会议室 | | | 上市公司 | 1 、 证券部经理 李素贤 | | | 接待人员 | 2 、 证券事务专员 蔡奕萍 | | | | 1 、公司十三五战略规划是什么？ | ...

证券代码：002317 编号：2019-013 广东众生药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-------------------------------------------|--------------------------------------------------------| | | | | | | √ | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 □一对一沟通 | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 1、董事、副总经理 2 、投资部经理 刘星 | 龙超峰 | | | | | | 时间 | 2019 年 12 月 20 日 | 9:30～11:00 | | 地点 | 广东众生药业股份有限公司会议室 | | | | 1 、兴全基金管理有限公司 | 杨世进 | | 上市公司 | 2 、兴全基金管理有限公司 | 季文华 | | 接待人员 ...

证券代码：002317 编号：2022-002 广东众生药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------| | | | | | | √ □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □一对一沟通 | | | □其他（请文字说明其他活动内容） | | | | 1 、方正证券股份有限公司 | 唐爱金 | | 参与单位名称 | 2 、方正证券股份有限公司 | 宋丹 | | 及人员姓名 | 3 、珠海横琴南山开源资产管理有限公司 4 、上海正享投资管理有限公司 | 詹世乾 袁婷婷 | | 时间 | ...

证券代码：002317 编号：2022-005 广东众生药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |---------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 □一对一沟通 | | | | √ □其他（电话会议） | | | | | 华鑫证券有限责任公司、广发证券股份有限公司、兴证全球 | | | | 基金管理有限公司、招商基金管理有限公司、银河基金管理 | | 参与单位名称 | | 有限公司、上银基金管理有限公司、中国人寿养老保险股份 | | 及人员姓名 | | 有限公司、华 ...

证券代码：002317 编号：2022-004 广东众生药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | √ | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 □一对一沟通 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 公司投资者 | | | 时间 | 2022 年 05 月 10 日 | 15:00～17:00 | | 地点 | 全景网"投资者关系互动平台"（ | http ...

证券代码：002317 编号：2022-006 广东众生药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |---------------------|------------------------------|-------------------------------------------------------| | | | | | | √ | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 □一对一沟通 | | | 其他（电话会议） | | | | | 珠海横琴南山开源资产管理有限公司、上海正享投资管理有 | | | | 限公司、深圳市安通私募证券基金管理有限公司、东莞市宏 | | | | 商资本投资有限公司、招商证券股份有限公司 | | | | 华鑫证券有限责任公司、汇添富基金管理股份有限公司、国 | | | | 金证券股份有限公司、深圳市中欧瑞博投资管理股份有限公 | | | | 司、长江养老保险股份有限公司、上海域秀资产管理有限公 | | | | ...

证券代码：002317 编号：2022-007 广东众生药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------------------------|--------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | | □现场参观 □一对一沟通 | | | 其他（ 2022 | 广东辖区上市公司投资者关系管理月活动投资 | | | 者集体接待日） | | | 参与单位名称 及人员姓名 | 公司投资者 | | | 时间 | 2022 年 9 月 22 日 15:50 | ～ 16:50 | | 地点 | 全景•路演天下（ | http://rs.p5w.net ） | | 上市公司 接待人员 | 1、董事长、总裁 2 、董事、副总裁、财务总监 | 陈永红 龙春 ...

Financial Performance - The company's revenue for Q3 2022 was ¥665,343,383.77, representing an increase of 8.45% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥46,496,210.61, a significant increase of 79.08% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥79,309,984.60, which decreased by 11.54% compared to the same period last year[6]. - The company reported a year-to-date revenue of ¥1,991,202,038.72, which is a 9.19% increase year-on-year[14]. - The company’s net profit for the year-to-date period was ¥248,731,479.51, reflecting a decrease of 20.73% compared to the same period last year[14]. - Total operating revenue for the current period reached ¥1,991,202,038.72, an increase of 9.2% compared to ¥1,823,582,996.89 in the previous period[37]. - Net profit for the current period was ¥246,324,247.33, a decrease of 19.8% from ¥307,197,888.72 in the same period last year[40]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥5,811,585,037.95, reflecting an increase of 18.56% from the end of the previous year[6]. - The equity attributable to shareholders at the end of Q3 2022 was ¥3,631,183,288.65, up by 4.47% from the end of the previous year[6]. - The company's total liabilities as of September 30, 2022, amounted to CNY 1,215,961,292.29, compared to CNY 524,197,608.58 at the beginning of the year, marking an increase of about 132.2%[33]. - The company's total liabilities increased to ¥2,119,650,597.21 from ¥1,363,840,852.63, representing a growth of 55.5%[36]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥139,886,612.94, showing a decrease of 56.55% year-on-year[6]. - The net cash flow from operating activities decreased by 56.55% to approximately CNY 139.89 million, primarily due to reduced cash inflows from operating activities[18]. - Cash flow from operating activities was ¥1,646,897,464.68, down from ¥1,810,933,745.63, showing a decrease of 9.0%[43]. - Cash inflow from other operating activities was ¥81,089,738.48, significantly higher than ¥49,112,805.62 in the previous period[46]. Investments and Expenses - Research and development expenses were ¥88,566,717.23, slightly up from ¥87,165,221.92, indicating a focus on innovation[40]. - Financial expenses surged by 1,892.07% to approximately CNY 60.45 million, mainly due to increased interest on financial liabilities and discounted notes[18]. - The company reported a financial expense of ¥60,446,456.11, significantly higher than ¥3,034,353.30 in the previous period, primarily due to increased interest expenses[40]. Shareholder Information - The company’s total number of ordinary shareholders reached 49,514, with the top two shareholders, Zhang Yuchong and Zhang Yuli, each holding 11.37% of shares[19]. - The company plans to raise a total of up to CNY 678.80 million through a private placement of A-shares, not exceeding 15% of the total share capital prior to the issuance, which amounts to 122,169,161 shares[24]. - The company has received the acceptance notice from the China Securities Regulatory Commission regarding its application for the private placement of shares[24]. Inventory and Receivables - Accounts receivable due within one year increased by 83.94% to approximately CNY 549.83 million, influenced by a reduction in large time deposits classified as current assets[15]. - The company’s inventory stock decreased by 46.99% to approximately CNY 80.35 million due to the implementation of equity incentives[15]. - The company’s inventory as of September 30, 2022, was CNY 449,515,933.12, showing a slight decrease from CNY 452,198,760.24 at the beginning of the year[30]. Other Financial Metrics - The basic earnings per share for Q3 2022 was ¥0.06, a 100% increase compared to the same period last year[6]. - Basic earnings per share decreased to ¥0.31 from ¥0.39, reflecting the decline in net profit[42]. - Deferred income increased by 62.73% to approximately CNY 53.28 million, reflecting an increase in government subsidies received[15]. - Deferred income increased to ¥53,284,159.24 from ¥32,744,803.82, indicating growth in future revenue recognition[36].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,325,858,654.95, representing a 9.57% increase compared to CNY 1,210,097,358.68 in the same period last year[28]. - The net profit attributable to shareholders of the listed company decreased by 29.73% to CNY 202,235,268.90 from CNY 287,798,418.61 year-on-year[28]. - The basic earnings per share fell by 30.56% to CNY 0.25, down from CNY 0.36 in the previous year[28]. - The total assets at the end of the reporting period increased by 9.56% to CNY 5,370,546,371.02 from CNY 4,901,980,877.51 at the end of the previous year[28]. - The net assets attributable to shareholders of the listed company rose by 2.78% to CNY 3,572,197,214.83 compared to CNY 3,475,652,725.99 at the end of the previous year[28]. - The net cash flow from operating activities was CNY 163,121,982.85, a decrease of 3.18% from CNY 168,481,856.57 in the same period last year[28]. - The company's weighted average return on equity was 5.66%, down from 7.75% in the previous year, reflecting a decrease of 2.09%[28]. - The company reported a significant increase in financial expenses by 1,911.20% due to higher interest expenses on financial liabilities and bill discounting[99]. - The company achieved a net increase in cash and cash equivalents of ¥76,176,234.37, a significant improvement of 116.23% compared to a decrease of ¥469,252,103.01 in the previous year[99]. Industry Context - The pharmaceutical industry in China experienced a revenue decline of 0.60% year-on-year, totaling RMB 1,400.78 billion in the first half of 2022[42]. - Total profit for the pharmaceutical industry decreased by 27.60% year-on-year, amounting to RMB 220.95 billion[42]. - The company acknowledges potential risks including industry policy risks, rising costs, R&D risks, and uncertainties in subsidiary performance[5]. - The company faces industry policy risks due to ongoing healthcare reforms and price reductions in drug procurement, which could adversely affect revenue[135]. - Rising costs of raw materials, labor, and environmental compliance are putting continuous pressure on the company's profitability[135]. Strategic Focus and Innovation - The company focuses on key therapeutic areas including ophthalmology, cardiovascular, respiratory, and digestive diseases, enhancing its product pipeline through both internal R&D and external partnerships[46]. - The company emphasizes innovation in drug development as its primary productivity driver, with a sustainable business model that includes innovative drugs, traditional Chinese medicine, and chemical generics[46]. - The company is committed to becoming a leading pharmaceutical health industry group in China, focusing on high-quality products and services[46]. - The company is focusing on a three-year strategic plan centered on "traditional Chinese medicine as the foundation, innovation leading, and focusing on specialty pharmaceutical health enterprises" to adapt to market changes[64]. - The company is investing in the development of broad-spectrum antiviral drugs and drugs for NASH and metabolic diseases, achieving significant results in innovation[68]. - The company is leveraging internet technologies and new business models to explore new retail transformations in the pharmaceutical sector[68]. - The company is focusing on high-barrier modified new drugs, with two polymer micelle formulations entering Phase I clinical trials[81]. - The company has 7 innovative drug projects currently in clinical trial stages, targeting liver diseases, respiratory diseases, and tumors[83]. Product Development and Market Position - The company is a leading creator and market leader of the Compound Thrombus-Relieving series, with its core product, the Compound Thrombus-Relieving Capsule, being a unique formulation listed in the National Essential Drug List and National Medical Insurance Directory, demonstrating significant clinical value and a high market share in the domestic ophthalmology market[47]. - The Brain Thrombus-Relieving Capsule, developed based on traditional Chinese medicine principles, is a unique product in the National Medical Insurance Directory, widely used for ischemic stroke prevention and treatment, with substantial growth potential and rich clinical evidence[47]. - The company has a strong market position in tuberculosis medications, with key products like Isoniazid Tablets and Pyrazinamide Tablets selected in multiple rounds of national procurement, indicating robust market opportunities[51]. - The company’s products, such as the Carboxymethylcysteine Oral Solution, have rapidly increased market share, demonstrating effective treatment for respiratory diseases[51]. - The company’s eye care products, including the Hydroxypropyl Methylcellulose Eye Drops, are recommended in multiple clinical guidelines, indicating strong market demand and growth potential[51]. - The company has achieved significant progress in the consistency evaluation of generic drugs, with 12 products passing the evaluation and 5 selected in national procurement[80]. Research and Development - The company has invested over 8% of its revenue in R&D for several consecutive years, establishing a robust research and development team of over 400 people[76]. - The company has established partnerships with leading CROs and academic institutions to enhance its drug development capabilities and foster innovation[76]. - The company is focusing on the continuous development of its product pipeline, including post-marketing evaluations and secondary development of traditional Chinese medicines[76]. - The company has successfully completed ethical approvals and data extraction for a real-world study involving over 5,000 ischemic stroke patients, further validating the efficacy of its products[79]. - The innovative drug ZSP1601 for treating non-alcoholic fatty liver disease has completed Phase Ib/IIa clinical studies, showing potential in reducing liver inflammation markers[87]. Operational Efficiency - The company adheres to a "sales-driven production" model, adjusting production plans based on sales progress and inventory levels, ensuring efficient operations[54]. - The company employs various procurement strategies, including competitive bidding and strategic sourcing, to manage raw material costs and ensure quality supply, mitigating risks associated with price and quality fluctuations[54]. - The company’s production strictly follows pharmaceutical management laws and GMP standards, ensuring high-quality manufacturing processes[54]. - The company has established a comprehensive supply chain management platform to enhance supplier relationships and market analysis capabilities[92]. Corporate Governance and Compliance - The company has a comprehensive corporate governance structure to protect the rights of shareholders and creditors, ensuring fair treatment[168]. - The company has not reported any major changes in risks faced during the reporting period, maintaining a stable risk profile[135]. - The company has not engaged in any related party transactions during the reporting period, indicating a focus on independent operations[186]. - The company has maintained compliance with environmental laws and regulations, continuously improving its environmental management systems and equipment[172]. Environmental Responsibility - The company has established an independent environmental health and safety department to oversee daily environmental protection work[160]. - The company has been recognized multiple times as a "Clean Production Enterprise" in Guangdong Province, emphasizing its commitment to environmental protection[167]. - The company implemented a pre-treatment process to reduce total phosphorus in wastewater, resulting in compliance with discharge standards[164]. - The company has a monitoring plan for pollutant emissions, conducting weekly and quarterly tests to ensure compliance[164]. - The company has actively participated in social responsibility initiatives, supporting local education, culture, health, and poverty alleviation efforts[172]. Shareholder Relations - The company plans to enhance its research and development capabilities in ophthalmology, respiratory diseases, non-alcoholic fatty liver disease, and oncology through the innovative drug projects[123]. - The company will not distribute cash dividends or issue bonus shares for the half-year period[143]. - A total of 5,780,000 restricted stocks were granted to 77 incentive objects under the 2022 restricted stock incentive plan, completed on March 22, 2022[150]. - The employee stock ownership plan includes 25 employees holding a total of 5,700,000 shares, representing 0.70% of the company's total equity[152].

Financial Performance - The company's revenue for Q1 2022 was ¥675,794,415.22, representing a year-on-year increase of 9.73% compared to ¥615,880,806.76 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2022 was ¥74,590,425.78, a 31.41% increase from ¥56,762,950.08 in Q1 2021[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥126,167,446.23, up 12.49% from ¥112,162,463.85 in the previous year[3]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.09, an increase of 28.57% from ¥0.07 in Q1 2021[3]. - The total operating revenue for the first quarter was CNY 675,794,415.22, an increase of 9.6% compared to CNY 615,880,806.76 in the same period last year[33]. - The net profit for the current period is approximately ¥73.61 million, compared to ¥54.85 million in the previous period, indicating an increase of about 34%[39]. - The total comprehensive income for the current period is approximately ¥78.82 million, compared to ¥61.66 million in the previous period, reflecting an increase of about 27.7%[39]. Cash Flow and Assets - The net cash flow from operating activities decreased by 48.86% to ¥25,671,106.19 from ¥50,198,713.06 in the same quarter last year[3]. - The company's cash and cash equivalents at the end of the period amounted to CNY 1,152,024,850.15, up from CNY 1,016,367,813.78 at the beginning of the year, reflecting a growth of 13.4%[26]. - The total assets at the end of Q1 2022 were ¥5,198,506,320.86, reflecting a 6.05% increase from ¥4,901,980,877.51 at the end of the previous year[3]. - The total liabilities increased to CNY 1,544,384,070.06 from CNY 1,363,840,852.63, marking an increase of 13.2%[32]. - The company's inventory at the end of the period was CNY 462,399,578.22, slightly up from CNY 452,198,760.24, showing an increase of 2.5%[26]. - The net cash flow from investing activities was -$115,090,246.22, an improvement from -$149,879,682.70 in the prior period[46]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 69,567[13]. - Zhang Yuchong and Zhang Yuli each hold 11.37% of shares, totaling 92,640,500 shares[13]. - The company has not identified any related party relationships among the top 10 shareholders[16]. - The total number of shares held by shareholder Lü Liangfeng is 11,868,194, including shares held through margin trading accounts[16]. Incentive Plans - The company approved a restricted stock incentive plan to grant 5.84 million shares at a price of 5.58 RMB per share[17]. - The restricted stock plan has a lock-up period of 12, 24, and 36 months, with specific release ratios of 40%, 30%, and 30%[17]. - The employee stock ownership plan is set to not exceed 5.7 million shares, representing 0.70% of the total share capital[21]. - The stock repurchase price for the employee stock ownership plan is also set at 5.58 RMB per share[21]. - The company completed the registration of the restricted stock incentive plan on March 22, 2022[18]. - The total number of shares granted in the adjusted incentive plan is 5.78 million shares[18]. Operational Strategies - The company has actively adapted to changes in the pharmaceutical industry and optimized its operational strategies, leading to sustained revenue growth[8]. - The company plans to expand its market presence and continue developing new products and technologies[24]. Borrowings and Financial Changes - The company experienced a 90.69% increase in short-term borrowings, rising to ¥362,307,690.00 from ¥190,000,000.00 in the previous year[10]. - The company's short-term borrowings rose significantly to CNY 362,307,690.00 from CNY 190,000,000.00, an increase of 90.6%[29]. - The company recorded a financial expense of approximately ¥13.72 million, compared to a financial income of approximately -¥0.31 million in the previous period[36]. - Cash inflow from financing activities amounted to $312,147,065.79, a decrease of approximately 33.9% compared to $472,307,422.06 last year[46]. - Cash outflow for debt repayment was $80,000,000.00, significantly lower than $261,000,000.00 in the previous period, showing a reduction of about 69.4%[46]. Research and Development - Research and development expenses increased to approximately ¥26.38 million from ¥23.74 million, which is an increase of about 11%[36]. - The company received FDA approval for the clinical trial of its innovative drug ZSP1273, aimed at preventing and treating influenza[25]. Audit and Reporting - The company did not undergo an audit for the first quarter report[47]. - The report was issued by the board of directors of Guangdong Zhongsheng Pharmaceutical Co., Ltd. on April 24, 2022[48].